Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.

about

Targeting CD6 for the treatment of experimental autoimmune uveitis.Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells

P2860

Q52689322-596F5281-8F52-4AFF-9CF6-5228E7162437 Q57816679-FB0F6BE1-021B-4AED-8CDA-67217341E9AF

P2860

Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.

Item

http://www.wikidata.org/entity/Q39033726

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@en

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@nl

type

Item

label

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@en

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@nl

prefLabel

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@en

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@nl

P1476

Itolizumab, a novel anti-CD6 m ...... t for management of psoriasis.

@en

P2093

Shraddha Uprety

http://www.w3.org/2001/XMLSchema#string

Sunil Dogra

http://www.w3.org/2001/XMLSchema#string

P2860

Relevance of CD6-mediated interactions in T cell activation and proliferation

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab

Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction.

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Pathogenesis and therapy of psoriasis.

P304

395-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2017.1279601

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Swaroop Hassan Suresh

P577

2017-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28064543

http://www.w3.org/2001/XMLSchema#string

Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.

about

P2860

P2860

Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698